Fate stock: buy or sell?

FATE stock price: $31.88 4.97% At close on February 26th, 2020

Updated on:
February 26th, 2020


Shares of Fate Therapeutics closed today at $31.88 after reaching a new all time high ($32.24) and climbed a super good 4.97%. On Friday FATE rocketed a dazzling 5.11%.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Should I buy Fate stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, 2 buy setups match with Fate stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Fate Therapeutics stock a buy?

Financial institutions and banks publish stock ratings everyday. Unfortunately, we couldn't detect any rating for FATE stock for the last month.

Fate stock analysis

Daily outlook

Shares of Fate Therapeutics closed today at $31.88 after reaching a new all time high ($32.24) and climbed a super good 4.97%.

Fate shares climbed 4.97% today and reached a new all time high at $32.24. On Friday, SMA100d and SMA200d crossed up triggering a rise of 8.58%. Since December when FATE stock price broke up the SMA200d line, it gained $18.21 (133.21%). FATE shows a strong short term uptrend with several rising tops and rising bottoms. Since its last bottom on February 7th, FATE climbed unceasignly breaking out to new all time highs.

FATE stock chart (daily)

Weekly outlook

Fate Therapeutics closed this week at $31.88 after topping to a new all time high ($32.24) and soared a very good 3.04%. This week was the 5th green week in a row. Last week FATE climbed an exceptional 6.66% in just one week. Late January FATE plunged a bloodcurdling -6.17% in just one week.

Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $21.00 resistance. Last week, SMA20w and SMA40w crossed up triggering a rise of 10.39%. Since price and SMA40w lines crossed up early December, FATE climbed $18.21 (133.21%).

FATE stock chart (weekly)

Fate stock price history

Fate stock went public on October 1st, 2013 with a price of $6.561. Since then, FATE stock surged a 386.00%, with an average of 64.30% per year. If you had invested $1,000 in Fate stock in 2013, it would worth $3,860.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Fate stock historical price chart

FATE stock reached all-time highs today with a price of $32.24.

Fate stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not found any price prediction for Fate Therapeutics stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Fate Therapeutics reported tiny results for 2018-Q4 on March. Fate Therapeutics stepped up Earnings per Share (EPS) by 4.20%, beating experts estimates of $-0.24. Fate Therapeutics posted $-0.25.
FATE earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Fate annual sales boosted an outstanding 15.44% to $4.74 million dollars from $4.11 marked in 2017. By contrast, its profit margin (compared to sales) plunged to -1,405.02%, that is $-66.60 million.

FATE annual Sales and Income evolution
2013$0.97 M-$-20.89 M-2151.4%-
2015$2.43 M150.36%$-29.99 M-1233.7%43.57%
2016$4.40 M81.08%$-33.46 M-760.2%11.57%
2017$4.11 M-6.72%$-42.95 M-1046.1%28.36%
2018$4.74 M15.44%$-66.60 M-1405.0%55.05%

Quarterly financial results

Fate posted $1.66 M in sales for 2018-Q4, a 61.89% improvement compared to previous quarter. Reported quarter earnings marked $-16.03 M with a profit margin of -964.90%. Profit margin skyrocketed a 670.77% compared to previous quarter when profit margin was -1,635.67%. When comparing turnover to same quarter last year, Fate Therapeutics sales marked an amazing increase and rocketed a 61.73%.
FATE quarterly Sales and Income evolution
2017-Q1$1.03 M-$-10.13 M-983.5%-
2017-Q2$1.03 M0.00%$-9.65 M-936.9%-4.74%
2017-Q3$1.03 M0.00%$-10.68 M-1036.9%10.67%
2017-Q4$1.03 M-0.29%$-12.50 M-1216.8%17.01%
2018-Q1$1.03 M-0.10%$-14.14 M-1377.7%13.11%
2018-Q2$1.03 M0.10%$-19.65 M-1913.7%39.04%
2018-Q3$1.03 M-0.10%$-16.78 M-1635.7%-14.61%
2018-Q4$1.66 M61.89%$-16.03 M-964.9%-4.50%

Fate ownership

When you are planning to invest in shares of a stock, it's always worth to check its ownership structure.

Fate shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.02% of all shares.

Bearish positions for FATE stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Fate:

Market cap$2.4 B
Total shares75.6 M
Float shares63.3 M
  - Institutional holdings (%)95.7%
  - Insider holdings (%)2.0%
Shares in short selling0.0%

Fate summary

Wednesday, February 26th, 2020
Day range$30.37 - $32.24
Previous close$30.37
Session gain4.97%
Average true range$1.34
50d mov avg$24.30
100d mov avg$19.62
200d mov avg$19.29
Daily patternlb03c
Weekly pattern lb02c

Fate performance

To better understand Fate Therapeutics performance you must becnhmark its gains with other related stocks in same sector or industry. For Fate, the comparison is made against .
FATEFate Therapeutics104.10%95.34%92.63%

Fate competitors

Unfortunately, we could not find any public company that could be defined as Fate competitor. This doesn't mean Fate does not have any competitor in the market, it's just we could not detected it.